Tenaya Therapeutics Reports the First Patient Dosing of TN-201 in the P-Ib Trial (MyPeak-1) for MYBPC3-Associated Hypertrophic Cardiomyopathy
Shots:
- The first patient has been dosed in the P-Ib trial evaluating the safety, tolerability & clinical efficacy of TN-201 (AAV-based gene therapy) for Myosin Binding Protein C3 (MYBPC3)-associated HCM at the Cleveland Clinic, Cleveland & Ohio. The trial will be conducted at ~12 US centers specializing in HCM care while initial data is expected in 2024
- Additionally, ~6 symptomatic adults were expected to enroll who have been diagnosed with MYBPC3-associated nonobstructive HCM & have an implantable cardioverter defibrillator & treat ~15 patients from the US & outside the US
- The first dose of TN-201 is 3E13 vg/kg associated with near-maximal efficacy in preclinical studies. The company plans to enroll patients at 6E13vg/kg & additional patients in the initial dose cohort
Ref: Globenewswire | Image: Tenaya Therapeutics
Related News:- BMS Highlighted Long-Term Follow-Up Results from Two P-III Studies of Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
